- Home
- PRLD vs IMMX Comparison
PRLD vs IMMX Comparison
Compare PRLD & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- IMMX
- Stock Information
- Founded
- PRLD 2016
- IMMX 2014
- Country
- PRLD United States
- IMMX United States
- Employees
- PRLD N/A
- IMMX N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- PRLD Health Care
- IMMX Health Care
- Exchange
- PRLD Nasdaq
- IMMX Nasdaq
- Market Cap
- PRLD 50.1M
- IMMX 50.1M
- IPO Year
- PRLD 2020
- IMMX 2021
- Fundamental
- Price
- PRLD $0.89
- IMMX $2.34
- Analyst Decision
- PRLD Strong Buy
- IMMX Strong Buy
- Analyst Count
- PRLD 2
- IMMX 1
- Target Price
- PRLD $4.50
- IMMX $7.00
- AVG Volume (30 Days)
- PRLD 137.5K
- IMMX 360.1K
- Earning Date
- PRLD 05-06-2025
- IMMX 06-10-2025
- Dividend Yield
- PRLD N/A
- IMMX N/A
- EPS Growth
- PRLD N/A
- IMMX N/A
- EPS
- PRLD N/A
- IMMX N/A
- Revenue
- PRLD $7,000,000.00
- IMMX N/A
- Revenue This Year
- PRLD N/A
- IMMX N/A
- Revenue Next Year
- PRLD N/A
- IMMX N/A
- P/E Ratio
- PRLD N/A
- IMMX N/A
- Revenue Growth
- PRLD N/A
- IMMX N/A
- 52 Week Low
- PRLD $0.61
- IMMX $1.26
- 52 Week High
- PRLD $6.80
- IMMX $2.71
- Technical
- Relative Strength Index (RSI)
- PRLD 51.42
- IMMX 61.49
- Support Level
- PRLD $0.77
- IMMX $1.89
- Resistance Level
- PRLD $1.00
- IMMX $2.50
- Average True Range (ATR)
- PRLD 0.11
- IMMX 0.17
- MACD
- PRLD -0.01
- IMMX 0.00
- Stochastic Oscillator
- PRLD 37.18
- IMMX 73.77
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.